Filtros

Buscador
Año
Mandaglio-Collados D, Lopez-Galvez R, Ruiz-Alcaraz AJ, Lopez-Garcia C, Roldan V, Lip GYH, Marin F, Rivera-Caravaca JM. Impact of particulate matter on the incidence of atrial fibrillation and the risk of adverse clinical outcomes: A review. Sci Total Environ. 2023 Jul 1;880:163352. doi: 10.1016/j.scitotenv.2023.163352. Epub 2023 Apr 4. PubMed PMID: 37023806.
AÑO: 2023; IF: 8.2
Fleurot I, Lopez-Galvez R, Barbry P, Guillon A, Si-Tahar M, Bahr A, Klymiuk N, Sirard JC, Caballero I. TLR5 signalling is hyper-responsive in porcine cystic fibrosis airways epithelium. J Cyst Fibros. 2022 Mar;21(2):e117-e121. doi: 10.1016/j.jcf.2021.08.002. Epub 2021 Aug 20. PubMed PMID: 34420900.
AÑO: 2022; IF: 5.4
Roldan V, Martinez-Montesinos L, Lopez-Galvez R, Garcia-Tomas L, Lip GYH, Rivera-Caravaca JM, Marin F. Relation of the 'Atrial Fibrillation Better Care (ABC) Pathway' to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists. J Pers Med. 2022 Mar 17;12(3):487. doi: 10.3390/jpm12030487. PubMed PMID: 35330486; PubMed Central PMCID: PMC8954236.
AÑO: 2022; IF: 3.508
Lopez-Galvez R, Rivera-Caravaca JM, Anguita Sanchez M, Sanmartin Fernandez M, Rafols C, Perez-Cabeza AI, Baron Esquivias G, Lekuona Goya I, Vazquez Rodriguez JM, Cosin Sales J, Arribas Ynsaurriaga F, Barrios V, Freixa-Pamias R, Marin F. Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study. Eur J Clin Invest. 2022 Sep;52(9):e13788. doi: 10.1111/eci.13788. Epub 2022 Apr 14. PubMed PMID: 35395094.
AÑO: 2022; IF: 5.5
Lopez-Galvez R, Marin F, Rivera-Caravaca JM. Predicting heart failure in atrial fibrillation patients: What about using biomarkers? Am Heart J. 2022 Sep;251:32-34. doi: 10.1016/j.ahj.2022.05.007. Epub 2022 May 7. No abstract available. PubMed PMID: 35537504.
AÑO: 2022; IF: 4.8